| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_ELP3_0004800 | Exon-Exon | chr8:27995215-27995408 | chr8:28137698-28137891 | 194 nt | 0.5052 |
| hsa_ELP3_0004900 | Exon-Exon | chr8:27995215-28017973 | chr8:28137698-28160456 | 579 nt | 0.4732 |
| hsa_ELP3_0004700 | Intron-Exon-Intron | chr8:27995215-28040781 | chr8:28137698-28183264 | 250 nt | 0.4160 |
| hsa_chr8_0287900 | Intergenic-Intergenic | chr8:27995341-28013504 | chr8:28137824-28155987 | 114 nt | 0.5175 |
| hsa_ELP3_0005000 | Intron-Exon-Intron | chr8:27997398-28018262 | chr8:28139881-28160745 | 250 nt | 0.3200 |
| hsa_chr8_0288000 | Intergenic-Intergenic | chr8:27999908-28000188 | chr8:28142391-28142671 | 281 nt | 0.3950 |
| hsa_chr8_0288100 | Intergenic-Intergenic | chr8:28002521-28003181 | chr8:28145004-28145664 | 661 nt | 0.3555 |
| hsa_chr8_0288200 | Intergenic-Intergenic | chr8:28002526-28003181 | chr8:28145009-28145664 | 656 nt | 0.3537 |
| hsa_ELP3_0005100 | Intron-Exon-Intron | chr8:28013435-28019595 | chr8:28155918-28162078 | 491 nt | 0.4542 |
| hsa_ELP3_0005400 | Intron-Exon-Intron | chr8:28013459-28023836 | chr8:28155942-28166319 | 250 nt | 0.3400 |
A study in human bladder cancer demonstrated that the circELP3 contributes to cancer progression and cisplatin resistance [Huang et al. DOI:10.3390/cells11091381].